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A B S T R A C T
Background: Current guidelines recommend that treatment of resistant cytomegalovirus (CMV) in solid organ
transplant (SOT) recipients must be based on genotypic analysis. However, this recommendation is not system-
atically followed.
Objectives: To assess the presence of mutations associated with CMV resistance in SOT recipients with suspected
resistance, their associated risk factors and the clinical impact of resistance.
Study design: Using Sanger sequencing we prospectively assessed the presence of resistance mutations in a na-
tion-wide prospective study between September 2013-August 2015.
Results: Of 39 patients studied, 9 (23%) showed resistance mutations. All had one mutation in the UL 97 gene
and two also had one mutation in the UL54 gene. Resistance mutations were more frequent in lung transplant
recipients (44% p = 0.0068) and in patients receiving prophylaxis ≥6 months (57% vs. 17%, p = 0.0180). The
mean time between transplantation and suspicion of resistance was longer in patients with mutations (239 vs.
100 days, respectively, p = 0.0046) as was the median treatment duration before suspicion (45 vs. 16 days,
p = 0.0081). There were no significant differences according to the treatment strategies or the mean CMV load
at the time of suspicion. Of note, resistance-associated mutations appeared in one patient during CMV pro
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phylaxis and also in a seropositive organ recipient. Incomplete suppression of CMV was more frequent in patients
with confirmed resistance.
Conclusions: Our study confirms the need to assess CMV resistance mutations in any patient with criteria of sus-
pected clinical resistance. Early confirmation of the presence of resistance mutations is essential to optimize the
management of these patients.
1. Background
Cytomegalovirus (CMV) is one of the most important pathogens af-
fecting solid organ transplant (SOT) recipients. In these patients, CMV is
a significant cause of morbidity and mortality associated with both in-
vasive disease and modulating effects in the host immune system [1,2].
The development of antiviral agents and preventive strategies over
the past decades have significantly improved patient outcomes, but they
have also promoted the development of antiviral-resistant CMV strains
that can significantly contribute to adverse clinical outcomes [3–6].
Antiviral drug resistance should be suspected when CMV viremia
or clinical disease persist in spite of prolonged antiviral therapy [7,8].
However, not all such cases are associated with genomic resistance mu-
tations. Genotypic testing is the routine method for detecting drug resis-
tance and the basis for the selection of alternative therapies [9].
Clinical suspicion of the development of resistance should be as-
sessed early for prompt initiation of the most appropriate therapy. How-
ever, virologic resistance is likely underdiagnosed since mutation assess-
ment is not systematically performed.
Several risk factors have been associated with CMV resistance
thereby conditioning the inclusion criteria of some studies [10]. The
present study was prospectively conducted within the context of the
Group for the Study of Infection in Transplantation (GESITRA), consti-
tuting one of its major lines of clinical research. The nationwide network
of Spanish hospitals has allowed the inclusion of a wide variety of solid
organ transplant recipients.
2. Objectives
The aim of this study was to assess the presence of mutations as-
sociated with CMV resistance in solid organ transplant recipients with
suspected resistance in a nation-wide study, as well as to determine the
associated risk factors and the clinical impact of resistance.
3. Study design
3.1. Setting and study population
We conducted a prospective observational study in nine hospitals
included in the Spanish Network for Research in Infectious Diseases
(REIPI). Adult solid organ transplant patients with suspected resistance
to antiviral drugs were included in the study from September 2013 to
August 2015. Resistance was suspected on the presence of progressive
or stable viral loads or if clinical symptoms persisted despite the use of
adequate antiviral treatment for at least 2 weeks [7,8].
The study was approved by the local Ethics Committees of the par-
ticipating hospitals and was endorsed by GESITRA.
The coordinating center was the Hospital Clinic of Barcelona, which
performed the genotypic resistance testing as well as the data analysis.
Patient treatment and follow-up were conducted as per the protocol of
each center. All patients were treated with standard-dose ganciclovir/
valganciclovir (GCV/VGCV) (adjusted to renal function). Monitoring
was based on locally quantified plasma CMV PCR tests. No standard-
ization was imposed. On suspicion of resistance, plasma samples were
frozen at −80 °C in the respective hospital and sent in batches to the
Microbiology Laboratory of Hospital Clínic every 4 months.
Data of interest at the time and beyond for each participant were
registered in a clinical database at each participating hospital. The resis-
tance mutations detected were also included in the database CMV infec-
tion and disease and acute cellular rejection were defined as previously
reported [7,8].
3.2. Microbiological studies
In the coordinating laboratory, extraction of DNA was performed in
500 μl of plasma of each sample using QIAsymphony system (Qiagen,
Hilden, Germany). CMV viral load was confirmed by PCR CMV Real
Time (Nanogen Advanced Diagnostics, Italy) according to the manufac-
tureŕs instructions.
Genotypic antiviral resistance testing was based on PCR amplifica-
tion of the CMV UL97 protein kinase gene (codons 400–670) in a sin-
gle fragment and the UL54 DNA polymerase gene (codons 300–1000) in
four fragments followed by Sanger nucleotide sequencing (see Supple-
mentary Material).
3.3. Data management and statistical analysis
Data were registered using the program OpenClinica 3.1 program
[copyright (C) 2005–2014, by LLC GNU Lesser General Public License
(GNU LGPL)]. Data were analyzed using Stata version 14.1 (Stata Corp.,
College Station, TX). We used the t-test or Wilcoxon rank-sum test to
compare continuous variables and the Fisher test to compare propor-
tions. Following univariate analysis, a logistic regression model was
constructed as an exploratory analysis to identify independent factors
significantly associated with the presence of a mutation. We did mul-
tivariate analyses by logistic regression with a stepwise forward model
(p⁠in < 0.05, p⁠out < 0.10 in the likelihood ratio test). Odds Ratios (OR)
and 95% confidence intervals (CI) were calculated for factors associated
with the presence of mutation. The threshold of statistical significance
was p < 0.05 (see Supplementary material).
4. Results
During the study period, we enrolled 43 adults who had undergone
solid organ transplantation and in whom CMV antiviral resistance was
suspected. Four were excluded from the analysis because sequencing
could not be carried out due to low CMV viral load. Finally, 39 patients
were included. Table 1 shows the baseline characteristics of the study
population.
The kidney was the most frequent type of organ transplant (44%)
followed by liver transplant (21%). Donor/recipient CMV serostatus was
mainly D+/R- (62%) with fewer R+ (39%). More than 20% of pa-
tients received depleting anti-lymphocyte antibodies as induction ther-
apy. The most common maintenance immunosuppressant regimen con-
sisted of tacrolimus, mycophenolate and steroids. Mammalian target of
rapamycin inhibitors (mTORi) were used in 4 patients (11%). Half of
the patients had received post-transplant prophylaxis and the most com-
mon schedule was ≤3 months (68%).
Based on genotype testing, 9 out of 39 (23%) patients tested showed
a CMV resistance mutation (Table 2). All of these 9 patients
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Table 1
Comparative baseline clinical characteristics of the study population.
Baseline
characteristic
Total
(39)
Without
mutations
(30)
With
mutations
(9) P-value
Age⁠a 52 (13)
[39]
54 (12)
[30]
46 (15)
[9]
0.0914⁠b
Sex (male) ⁠c 30(77%) 23 (77%) 7 (78%) 1.0000⁠d
Type of Transplant ⁠c
Kidney 17
(44%)
15 (50%) 2 (22%) 0.2512⁠4
Heart 6 (15%) 5 (17%) 1 (11%) 1.0000
Lung 5 (13%) 1 (3%) 4 (44%) 0.0068
Liver 8 (21%) 6 (20%) 2 (22%) 1.0000
Kidney-
pancreas
3(8%) 3 (10%) 0 (0%) 1.0000
CMV serostatus ⁠c
D+/R- 24
(62%)
16 (53%) 8 (89%) 0.1152⁠d
D+/R+ 14
(36%)
13 (43%) 1 (11%) 0.1189
D-/R+ 1(3%) 1 (3%) 0 (0%) 1.0000
Induction therapy ⁠3
Basiliximab 19
(49%)
17(57%) 2 (22%) 0.1274⁠d
Depleting anti-
lymphocyte
antibodies
9 (23%) 8 (27%) 1 (11%) 0.6542
Initial maintenance ⁠c
Cyclosporine 5 (14%) 3(12%) 2 (22%) 0.5716⁠d
Tacrolimus 30
(86%)
23(88%) 7 (78%) 1.0000
Mycophenolate
mofetil
31(89%) 22 (85%) 9 (100%) 0.1602
Steroids 27
(77%)
22 (85%) 5 (56%) 0.4161
Use of m-tor
inhibitors
4 (11%) 2 (8%) 2 (22%) 0.2226
CMV Prophylaxis schedule ⁠c
≤3 months 13
(68%)
10 (83%) 3 (43%) 1.0000⁠d
≥6 month 6 (32%) 2 (17%) 4(57%) 0.0180
a Arithmetic Mean (SD) [n].
b t-test.
c n (column percentage).
d Fisher’s exact test.
Table 2
Resistance mutations in the UL97 and UL54 genes.
Patient
Mutation
detected
UL97
Ratio⁠a
GCV
Mutation
detected
UL54
Ratio⁠a GCV/
POS/CDV
10 A594V 8.3
19 M460V 8.3
29 9.2
30 C592G 2.9
34 H520Q 10
35 M460V 8.3 P522A 3/1/4.1
36 L595S 9.2
38 M460V 8.3
42 M460I 5 D413A 6.5/0.8/11
a IC⁠50 of mutant/IC⁠50 of wild type.
had one mutation in the UL 97 gene: 8 with a high-level and one patient
with a low-level GCV resistance mutation (C592G) [11]. Two patients
also had one mutation in the UL54 gene, D413N and P522A respec-
tively; both mutations are associated with high-grade resistance to GCV
and cidofovir (CDV), but neither of the two was to POS [9]. Addition-
ally, 5 mutations of unknown significance were detected, all of which
were in the UL54 gene (G604S, V679A, Y708H, S895N, L1018P). One
UL97 drug-sensitive mutation (N510S) and several UL54 drug-sensitive
mutations (S655L, N685S, A885T, S897L, N898D) were also found [11].
The presence of resistance mutations was significantly higher in
lung transplant recipients (44% p = 0.0068) (Table 1). Although D+/
R- CMV serostatus was more frequently reported among patients with
mutations, the differences did not reach statistical significance. In ad-
dition one patient in this group was CMV seropositive. Longer prophy-
laxis (≥6 months) was more frequent in patients with resistance (57%
vs. 17%, p = 0.0180).
Moreover, the presence or not of resistance mutations was compa-
rable regarding at onset and beyond the time of resistance suspicion
(Table 3). The mean time between transplantation and time of suspicion
was longer in the group with resistance mutations (239 vs. 100 days,re-
spectively, P = 0.0046), as was the median treatment duration before
suspicion of resistance (45 vs. 16 days, p = 0.0081). There were no sig-
nificant differences between the two groups in the treatment strategies
at the time of suspicion of resistance, the mean CMV load or the pres-
ence of symptoms at suspicion. CMV disease was diagnosed in 49% of
patients although biopsy confirmation was achieved in only 3 patients.
Viral syndrome was the most frequent clinical presentation. All the pa-
tients were receiving standard doses GCV/VGCV doses at the time of
suspicion and clinicians empirically modified the treatment accordingly.
Patients without mutations mainly received increased doses of GCV or
VGCV (73%, p = 0.0153), while in patients with mutations mTORi was
added or switched to (67%, p = 0.0039). According to the outcome
at 3 months, patients with resistance more frequently had incomplete
suppression of CMV replication (67% vs. 30%, p = 0.0631). However,
there were no differences in the development of graft rejection (not di-
rectly related to CMV infection) or mortality. Of the variables associ-
ated with the presence of resistance mutations in the univariate analy-
ses, lung transplantation was the only variable independently associated
with increased risk for this mutation (OR 23.20, 95% CI 2.13–252.69)
(see Supplementary Material).The area under the ROC curve (AUC) for
the multivariate model was 0.71 (95% CI, 0.48–0.93) (see Supplemen-
tary material).
Table 4 shows the clinical and virological data of SOT recipients with
known CMV resistance mutations.
5. Discussion
The detection of drug resistance in CMV has important implications
for patient management, as resistance can have an impact on morbidity
and graft survival in transplant recipients [12]. However, clinical (clini-
cal profile) and virologic resistance (laboratory evidence) are not always
linked [13].
In our study, only 23% of the patients with suspected resistance
showed mutations associated with resistance confirmed by genotypic
methods, thereby emphasizing the relevance of antiviral resistance test-
ing whenever resistance is suspected. Unfortunately, it is not widely
available and usually cases are presumed to be CMV drug-resistant
based only on the lack of clinical and virological response to therapy
[14].
In the present study, the presence of mutations was associated with
lung transplantation, prophylaxis ≥6 months, a higher mean time be-
tween transplantation and suspicion of resistance and longer previous
treatment with GCV or VGCV. However, the 9 patients with confirmed
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Table 3
Comparison of the data at the onset and beyond the suspicion of resistance.
Characteristic Total (39) Without mutations (30) With mutations (9) P-value
Transplant and time of suspicion (days) ⁠5 118 (169)[39] 100 (145) [30] 239 (204) [9] 0.0046⁠6
Days of therapy before suspicion ⁠5 17 (23) [39] 16 (8) [30] 45 (58) [9] 0.0081⁠6
Treatment at the time of suspicion ⁠3
Prophylaxis
Pre-emptive treatment
Disease treatment
1 (3%)
26 (67%)
12 (31%)
0
21 (70%)
9 (30%)
1 (11%)
5(56%)
3(33%)
0.2308⁠4
0.4472
1.0000
CMV viral load at the time of suspicion(c/ml) ⁠1 147.836 (515.419) [39] 178.870 (585.809) [30] 44.390 (47.105) [9] 0.4997⁠2
Symptoms at moment of suspicion ⁠3
Viral syndromea
Gastrointestinal disease
Pneumonitis
Hepatitis
Disseminated (>1 end organ)
19 (49%)
9
6
2
1
1
14 (47%)
8
4
1
1
0
5 (56%)
1
2
1
0
1
1.000⁠4
Strategy on suspicion ⁠3
Increase dose GCV/VGCV alone
Switch or add foscanet
Switch or add mTORi
24 (62%)
8 (21%)
10 (26%)
22 (73%)
4(13%)
4(13%)
2 (22%)
4 (44%)
6 (67%)
0.0153⁠4
0.0651
0.0039
Viral Response ⁠3
Total suppression of CMV replication
Incomplete suppressión
24 (62%)
15 (38%)
21(70%)
9 (30%)
3 (33%)
6 (67%)
0.0631⁠4
Final outcome ⁠3
Graft rejection
Dead
5 (13%)
3 (8%)
3 (10%)
2 (7%)
2 (22%)
1 (11%)
0.5716⁠4
0.5558
⁠aPresence of fever >38 °C (for at least 2 days in a 4 day period) associated with leucopenia, thrombocytopenia or increase in transaminases.
1 Median (IQR)[n].
2 Wilcoxon Rank Sun test.
3 n (column percentage).
4 Fisher’s exact test.
5 Arithmetic Mean (SD) [n].
6 t-test.
resistance presented one or more risk factor to develop resistance de-
scribed in other studies (10).
One of the most important findings of this study is that the de-
velopment of GCV resistance is associated with prolonged use of GCV
or VGCV. It is well known that drug resistance generally occurs after
lengthy drug exposure with incomplete viral suppression, resulting in
increasing viral load or disease despite therapy [7,11]. In the present
study, patients with confirmed CMV resistance mutations had received
longer antiviral treatment than patients without mutations. On the other
hand, patients receiving antiviral prophylaxis for ≥6 months more fre-
quently presented confirmed GCV-resistant CMV than those who re-
ceived GCV less than three months. Although previous studies have ar-
gued that extending VGCV prophylaxis from 100 days to 200 days did
not significantly affect the incidence of GCV resistance, the results of our
study suggest the opposite [15]. During CMV prophylaxis the incidence
of GCV resistance is low [4], but it should not be ignored as shown in
one of the patients studied. We observed that lung transplant recipients
had the highest incidence of GCV resistance in accordance with previ-
ous reports [10]. Although it has been proposed that this may be associ-
ated with a specific immunosuppression protocol risk, local organ CMV
load, or anatomical factors, it is important to note that lung transplant
patients receive prophylaxis for a longer period of time. Four out of 5
patients who had undergone lung transplantation in our study presented
resistance (80%) and all had received long antiviral prophylaxis of be-
tween 6 and 12 months as recommended by clinical guidelines [7,8].
The other group of patients with a higher risk of GCV resistance was
that of CMV D+/R- organ recipients [16]. Although not statistically sig-
nificant, probably due to the low number of patients included in the
study, 89% of patients with mutations associated with resistance were
D+/R-. However, resistance can also occur in seropositive organ recip-
ients, as observed in one patient in the present study.
Similar to other reports, the use of anti-lymphocyte antibodies as in-
duction therapy was not associated with the emergence of resistance in
our study, but this may be due to the low number of patients included
[13]. Surprisingly, we did not observe significant differences in CMV vi-
ral load at the time of suspicion between the two groups of patients. This
result contrasts with previous studies, in which higher viral loads were
a risk factor for GCV resistance [4]. Thus, it is important to suspect GCV
resistance when viral load increases or does not decrease independently
of viral load.
Although clinical risk factors for drug resistance are becoming better
defined, resistance should be confirmed by diagnostic laboratory test-
ing in order to support therapeutic decisions related to the switching to
therapies with potential adverse effects [7,8]. In many instances, em-
piric treatment is used until genotypic analysis results are available.
Some mutations associated with low levels of resistance can be over-
come by increasing doses of GCV [17]. This probably explains why
doses of GCV were increased on suspicion of resistance. As plasma GCV
levels were not available, it cannot be ruled out that suboptimal drug
levels were maintained for prolonged periods. However, the only pa-
tient with a low-grade mutation in our study did not respond to high
doses of GCV, and thus, other factors likely contributed to treatment
failure, as previously suggested [18]. In addition, neither can we rule
out the possible accumulation of different mutated strains under antivi-
ral selective pressure not detected by Sanger sequencing [9,19,20].
Increasing evidence is available regarding the antiviral effects of
mTORi; these drugs have also been successfully used in the management
of SOT recipients with resistance mutations [21]. Interestingly, three of
4 patients with mutations not receiving mTORi (patients 10, 38 and 42)
presented bad prognosis.
The consequences of drug-resistant CMV strains may vary broadly
from asymptomatic viremia to tissue-invasive disease and unfavorable
clinical outcomes [5]. Incomplete suppression was more frequent in pa-
tients with virological resistance, which may be a risk factor for the de
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Table 4
Clinical and virological data in solid organ transplant recipients with a cytomegalovirus resistance mutation.
Patient
Type of
Transplant
(CMV
serostatus)
Induction
therapy
Prophylaxis
received
(months)
Treatment at the time
of suspicion ⁠a (days of
therapy)
CMV mutation
(days post-TX)
CMV viral load at
the time of
suspicion (copies/
ml)
Symptomatic at
the time of
suspicion
Therapeutic adaptation at
the time of suspicion Outcome⁠b
10 Liver
(D+/R−)
No 0 Preemptive therapy.
VGCV 450 mg/12 h
(15d)
UL97: A594 V
(63 d)
9.300 c/ml No Increased GCV Total suppression
Cell-mediated
rejection
19 Kidney
(D+/R+)
Basiliximab 1M Disease VGCV
450 mg/12 h (60d)
UL97: M460 V
(235 d)
11.234 c/ml Viral syndrome ⁠c
Suspected
gastritis
Increased GCV/
Everolimus/POS
Incomplete
suppression,
successive
reactivations
29 Heart
(D+/R−)
No 3M Preemptive therapy
GCV 2.5 mg/Kg/12 h
(84d)
UL97: L595S (350
d)
154.486 c/ml No increased GCV Incomplete
suppression,
successive
reactivations
30 Kidney
(D+/R−)
D.A.L 3M Disease VGCV
450 mg/12 h (45)
UL97: C592G
(102 d)
11.605 c/ml Suspected colitis Increased GCV/Sirolimus Incomplete
suppression,
successive
reactivations
34 Lung
(D+/R−)
No 6 M Prophylaxis VGCV
900 mg/24 h (180d)
UL97: H520Q
(210 d)
33.772 c/ml Confirmed
pneumonitis
POS/Sirolimus Total resolution
35 Lung
(D+/R−)
No 7M Preemptive therapy
VGCV 900 mg/12 h
(20d)
UL97:M460 V
UL54: P522A
(235 d)
68.494 c/ml No POS/Sirolimus Total resolution
36 Lung
(D+/R−)
No 6M Preemptive therapy
GCV 10 mg/Kg/12 h
(26)
UL97: L595S (210
d)
38.700 c/ml No Increased GCV/
Everolimus
Total resolution
38 Liver
(D+/R−)
No 0 Disease VGCV
900 mg/12 h (45d)
UL97: M460 V
(340 d)
11.375 c/ml Confirmed
pneumonitis and
retinitis
VGCV/POS Incomplete
suppression Death
42 Lung
(D+/R−)
Basiliximab 12M Preemptive therapy
GCV 7.5 mg/Kg/12 h
(200d)
UL97: M460I
UL54: D413N
(400 d)
2.800 c/ml No Increased GCV/
Leflunomide
Incomplete
suppression Cell-
mediated rejection
CMV, cytomegalovirus; D, donor; R, recipient; TX, transplantation; GCV, ganciclovir. VGCV, valganciclovir; POS, foscarnet; D.A.L. depleting anti-lymphocyte antibodies.
a Drug/doses.
b Outcomes (CMV replication, viral response, rejection and mortality) at 3 months.
c Presence of fever >38 °C (for at least 2 days in a 4 day period) associates with leucopenia, thrombocytopenia or increase in transaminases.
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velopment of multidrug resistance or a worse evolution. Nonetheless,
we were only able to analyze patient data up to 3 months after the sus-
picion of resistance.
In our study, genotypic testing showed that the 9 patients with resis-
tance mutations presented one of the “canonical” mutations in the viral
UL97 kinase gene [11]. In addition, mutations in the UL54 gene were
detected in 2 lung transplant patients. While UL97 mutations generally
anticipate UL54 mutations and confer only GCV resistance, CMV strains
with mutations in both UL97 and UL54 have higher levels of phenotypic
resistance in vitro, indicating that they might have an additive effect on
the GCV susceptibility of an isolate, with significant clinical repercus-
sions. In our study, of the 2 patients with mutations in the UL54 gene,
one presented cellular rejection but the other showed total resolution.
Furthermore, mutations in UL54 induced by therapy with one antiviral
agent can confer cross-resistance to other antiviral agents used to treat
CMV even without previous exposure [22], as has been demonstrated
in our study. An ongoing difficulty with interpretation of UL54 muta-
tions is the relatively frequent occurrence of natural sequence polymor-
phisms of unknown significance. In our study we found 5 of these poly-
morphisms, making the characterization of the resistance phenotype of
previously unrecognized mutations essential for interpretation of geno-
typic data [23].
In the cohort of patients studied, 77% had no evidence of resistance
mutations. We used Sanger sequencing with which a mutation can only
be detected if it is present in more than 20% of the virus population.
Hence, it is possible that mutations in minority virus variants at the time
of sampling remained undetected, and only deep sequencing techniques
can fully describe the kinetics of the emergence of resistant mutations
[24,25].
The limitations of the present study include the modest sample size
and the groups are not well balanced. Thus our results should be con-
firmed in a large and well balanced cohort. Another of the main limita-
tions of this study is that the analysis of GCV resistance of the mutations
was performed only when suspected. We performed a multicenter study
to cover the diversity of clinical and virological practices across Span-
ish centers without exclusion criteria. We included only patients not
responding to therapy despite adequate antiviral treatment since these
patients represent the group with the highest risk of antiviral-resistant
CMV, avoiding unnecessary testing of other patients.
In conclusion, our study confirms the need to assess CMV resistance
mutations in any patient with criteria of suspected clinical resistance.
Early confirmation of the presence of resistance mutations is essential to
optimize the management of these patients.
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